Dersimelagon (MT-7117) is an orally active, selective melanocortin 1 receptor (Induced pigmentation in a dose-dependent manner.
Minimum pigmentation effective dose was 1 mg/kg.
Pigmentation diminished 4 weeks after cessation of treatment in the 1, 3 and 10 mg/kg groups and 16 weeks after cessation in the 30 mg/kg group.
[1]. T. Suzuki, et al. Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist. Skin Health Dis. 2022; 2(1):e78.
[2]. Erwin AL, et al. Porprias in the Age of Targeted Therapies. Diagnostics (Basel). 2021;11(10):1795. Published 2021 Sep 29.
















